Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 701–800 of 1,021
Abe, Y., & Tanaka, N. (2016) · BioMed Research International · doi:10.1155/2016/7969286 · Cited by 104
Genetic Alterations of TRAF Proteins in Human Cancers
Zhu, S., Jin, J., Gokhale, S., Lu, A. M., Shan, H., Feng, J., & Xie, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02111 · Cited by 108
Kuna, R. S., & Field, S. J. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r088328 · Cited by 92
Friedlaender, A., Banna, G. L., Malapelle, U., Pisapia, P., & Addeo, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00166 · Cited by 106
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 100
Updated Prognostic Factors in Localized NSCLC
Garinet, S., Wang, P., Mansuet‐Lupo, A., Fournel, L., Wislez, M., & Blons, H. (2022) · Cancers · doi:10.3390/cancers14061400 · Cited by 109
Kim, D., Joung, J.-G., Sohn, K.-A., Shin, H., Park, Y. R., Ritchie, M. D., & Kim, J. H. (2015) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2013-002481 · Cited by 94
Hierro, C., Rodon, J. A., & Tabernero, J. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.027 · Cited by 99
Kim, Y.-A., Cho, D.-Y., Dao, P., & Przytycka, T. M. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv247 · Cited by 97
Weeden, C. E., Ah-Cann, C., Holik, A. Z., Pasquet, J., Garnier, J.-M., Mérino, D., Lessène, G., & Asselin-Labat, M.-L. (2018) · Oncogene · doi:10.1038/s41388-018-0268-2 · Cited by 97
Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
Piperdi, B., Merla, A., & Perez-Soler, R. (2014) · Drugs · doi:10.1007/s40265-014-0182-z · Cited by 102
Dysregulation of the Keap1–Nrf2 pathway in cancer
Leinonen, H. M., Kansanen, E., Pölönen, P., Heinäniemi, M., & Levonen, A.-L. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150048 · Cited by 92
Exploring cancer genomic data from the cancer genome atlas project
Lee, J. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.11.145 · Cited by 99
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
Brennan, K., Shin, J. H., Tay, J. K., Prunello, M., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-17298-x · Cited by 96
Beane, J., Mazzilli, S. A., Campbell, J. D., Duclos, G. E., Krysan, K., Moy, C. H., Perdomo, C., Schäffer, M., Liu, G., Zhang, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09834-2 · Cited by 103
p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas
Hsieh, M.-H., Choe, J. H., Gadhvi, J. G., Kim, Y. J., Arguez, M. A., Palmer, M., Gerold, H., Nowak, C. M., Do, H., Mazambani, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.027 · Cited by 99
Patient-derived cell line, xenograft and organoid models in lung cancer therapy
Huo, K.-G., D’Arcangelo, E., & Tsao, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-154 · Cited by 108
Vaping, Environmental Toxicants Exposure, and Lung Cancer Risk
Shehata, S. A., Toraih, E. A., Ismail, E. A., Hagras, A. M., Elmorsy, E. M., & Fawzy, M. S. (2023) · Cancers · doi:10.3390/cancers15184525 · Cited by 120
Hippo and TGF-β interplay in the lung field
Saito, A., & Nagase, T. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00238.2015 · Cited by 91
Aberrant Keap1 methylation in breast cancer and association with clinicopathological features
Barbano, R., Muscarella, L. A., Pasculli, B., Valori, V. M., Fontana, A., Coco, M., la Torre, A., Balsamo, T., Poeta, M. L., Marangi, G. F., et al. (2013) · Epigenetics · doi:10.4161/epi.23319 · Cited by 92
Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations
Campbell, J. D., Lathan, C. S., Sholl, L. M., Ducar, M. A., Vega, M., Sunkavalli, A., Lin, L., Hanna, M., Schubert, L., Thorner, A. R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6108 · Cited by 98
Tang, K.-J., Constanzo, J. D., Venkateswaran, N., Melegari, M., Ilcheva, M., Morales, J. C., Skoulidis, F., Heymach, J. V., Boothman, D. A., & Scaglioni, P. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2603 · Cited by 91
Molecular cancer prevention: Current status and future directions
Maresso, K. C., Tsai, K. Y., Brown, P. H., Szabo, E. M., Lippman, S. M., & Hawk, E. T. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21287 · Cited by 101
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Saha, A., O’Connor, R. S., Thangavelu, G., Lovitch, S. B., Dandamudi, D. B., Wilson, C. B., Vincent, B. G., Tkachev, V., Pawlicki, J. M., Furlan, S. N., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85796 · Cited by 98
Emerging therapeutic agents for lung cancer
Dholaria, B., Hammond, W. A., Shreders, A. J., & Lou, Y. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0365-z · Cited by 97
Huang, H., Zhang, W., Pan, Y., Gao, Y., Deng, L., Li, F., Li, F., Ma, X., Hou, S., Xu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0449 · Cited by 111
Wu, Q., Tian, Y., Zhang, J., Tong, X., Huang, H., Li, S., Zhao, H., Tang, Y., Yuan, C., Wang, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716589115 · Cited by 91
The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Saito, A., Horie, M., Micke, P., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113611 · Cited by 90
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Pennycuick, A., TEIXEIRA, V. H., AbdulJabbar, K., Raza, S. E. A., Lund, T., Akarca, A. U., Rosenthal, R., Kalinke, L., Chandrasekharan, D. P., Pipinikas, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1366 · Cited by 103
Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics
Stella, G. M., Luisetti, M., Pozzi, E., & Comoglio, P. M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70009-2 · Cited by 99
Zheng, X., Zhao, Q. C., Wu, H., Li, W., Wang, H., Meyer, C. A., Qin, Q., Xu, H., Zang, C., Jiang, P., et al. (2014) · Genome biology · doi:10.1186/preaccept-9737754001327268 · Cited by 92
Effects of Charged Particles on Human Tumor Cells
Held, K. D., Kawamura, H., Kaminuma, T., Paz, A., Yoshida, Y., Liu, Q., Willers, H., & Takahashi, A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00023 · Cited by 107
Hayashi, T., Desmeules, P., Smith, R. S., Drilon, A., Somwar, R., & Ladanyi, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2343 · Cited by 90
Lean Big Data integration in systems biology and systems pharmacology
Ma’ayan, A., Rouillard, A. D., Clark, N. R., Wang, Z., Duan, Q., & Kou, Y. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.001 · Cited by 91
Hao, C., Wang, L., Peng, S., Cao, M., Li, H., Hu, J., Huang, X., Liu, W., Zhang, H., Wu, S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.024 · Cited by 95
Hidalgo, M. R., Çubuk, C., Amadoz, A., Salavert, F., Carbonell‐Caballero, J., & Dopazo, J. (2016) · Oncotarget · doi:10.18632/oncotarget.14107 · Cited by 111
Genome-wide identification of transcription factors that are critical to non-small cell lung cancer
Zhang, D.-L., Qu, L.-W., Ma, L., Zhou, Y., Wang, G., Zhao, X., Zhang, C., Zhang, Y., Wang, M., Zhang, M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.020 · Cited by 97
LUBAC determines chemotherapy resistance in squamous cell lung cancer
Ruiz, E. J., Diefenbacher, M. E., Nelson, J. K., Sancho, R., Pucci, F., Chakraborty, A., Moreno, P., Annibaldi, A., Liccardi, G., Encheva, V., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180742 · Cited by 94
Clinical applications of nanomedicines in lung cancer treatment
Norouzi, M., & Hardy, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.009 · Cited by 98
Mutation profile of non-small cell lung cancer revealed by next generation sequencing
Chang, Y., Tu, S.-J., Chen, Y., Liu, T., Lee, Y.-T., Yen, J.-C., Fang, H., & Chang, J. (2021) · Respiratory Research · doi:10.1186/s12931-020-01608-5 · Cited by 101
Targeting NRF2 to treat cancer
Sivinski, J., Zhang, D. D., & Chapman, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.003 · Cited by 96
Mazzone, P. J., Bach, P. B., Carey, J., Schonewolf, C. A., Bognar, K., Ahluwalia, M. S., Cruz-Correa, M. R., Gierada, D. S., Kotagiri, S., Lloyd, K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0519 · Cited by 104
ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis
Liu, J., Cho, S.-N., Akkanti, B. H., Jin, N., Mao, J., Long, W., Chen, T., Zhang, Y., Tang, X., Wistub, I. I., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.014 · Cited by 89
An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer
Noguchi, S. F., Saito, A., Horie, M., Mikami, Y., Suzuki, H. I., Morishita, Y., Ohshima, M., Abiko, Y., Mattsson, J. S. M., König, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3328 · Cited by 100
RADIA: RNA and DNA Integrated Analysis for Somatic Mutation Detection
Radenbaugh, A. J., Ma, S., Ewing, A., Stuart, J. M., Collisson, E. A., Zhu, J., & Haussler, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111516 · Cited by 89
Daemen, A., Liu, B., Song, K., Kwong, M., Gao, M., Hong, R., Nannini, M., Peterson, D., Liederer, B. M., de la Cruz, C., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.003 · Cited by 88
Aggarwal, C., Redman, M. W., Lara, P. N., Borghaei, H., Hoffman, P. C., Bradley, J. D., Newman, A. J., Feldman, M. J., Minichiello, K., Miao, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.041 · Cited by 89
Anusewicz, D., Orzechowska, M., & Bednarek, A. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-77284-8 · Cited by 108
NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma
Shah, P. A., Huang, C., Li, Q., Kazi, S. A., Byers, L. A., Wang, J., Johnson, F. M., & Frederick, M. J. (2020) · Cells · doi:10.3390/cells9122677 · Cited by 106
Wrangle, J. M., Machida, E. O., Danilova, L., Hulbert, A., Franco, N. C., Zhang, W., Glöckner, S. C., Tessema, M., Neste, L. V., Easwaran, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2109 · Cited by 104
Wang, D. Y. Q., Pham, N., Tong, J., Sakashita, S., Allo, G., Kim, L., Yanagawa, N., Raghavan, V., Wei, Y., To, C., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30472 · Cited by 93
Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations
Gerber, D. E., Gandhi, L., & Costa, D. B. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e353 · Cited by 89
PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses
Medina, P. J., & Adams, V. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1714 · Cited by 93
Nazarov, P. V., Muller, A., Kaoma, T., Nicot, N., Máximo, C., Birembaut, P. L., Tran, N. L., Dittmar, G., & Vallar, L. (2017) · BMC Genomics · doi:10.1186/s12864-017-3819-y · Cited by 100
Cardnell, R. J., Li, L., Sen, T., Bara, R. O., Tong, P., Fujimoto, J., Ireland, A. S., Guthrie, M. R., Bheddah, S., Banerjee, U., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20621 · Cited by 93
Hinkson, I. V., Davidsen, T. M., Klemm, J. D., Chandramouliswaran, I., Kerlavage, A. R., & Kibbe, W. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00083 · Cited by 88
Chen, X., Chang, C., Spoerke, J. M., Yoh, K. E., Kapoor, V., Baudo, C. D., Aimi, J., Yu, M., Liang-Chu, M. M. Y., Suttmann, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1593 · Cited by 94
Prevalence and role of HER2 mutations in cancer
Cocco, E., Lopez, S., Santin, A. D., & Scaltriti, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.010 · Cited by 92
“NRF2 addiction” in lung cancer cells and its impact on cancer therapy
Hammad, A., Namani, A., Elshaer, M., Wang, X. J., & Tang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.016 · Cited by 91
Treatment of advanced squamous cell carcinoma of the lung: a review.
Derman, B. A., Mileham, K. F., Bonomi, P., Batus, M., & Fidler, M. J. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.06.07 · Cited by 101
Kaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87
Self-citationXu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Kim, L., & Tsao, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00197013 · Cited by 90
Sumi, N. J., Kuenzi, B. M., Knezevic, C. E., Remsing Rix, L. L., & Rix, U. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00368 · Cited by 84
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Cretella, D., Digiacomo, G., Giovannetti, E., & Cavazzoni, A. (2019) · Cancers · doi:10.3390/cancers11091318 · Cited by 92
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 94
PROTAC therapy as a new targeted therapy for lung cancer
Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.011 · Cited by 87
Keap1-Nrf2 pathway: a key mechanism in the occurrence and development of cancer
Chen, F., Xiao, M., Hu, S., & Wang, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1381467 · Cited by 118
Modulation of NF-κB/miR-21/PTEN Pathway Sensitizes Non-Small Cell Lung Cancer to Cisplatin
Yang, Z., Fang, S., Di, Y., Ying, W., Tan, Y., & Gu, W. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121547 · Cited by 87
Lococo, F., Gandolfi, G., Rossi, G., Pinto, C., Rapicetta, C., Cavazza, A., Cesario, A., Galeone, C., Paci, M., & Ciarrocchi, A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.020 · Cited by 87
Biological function and histone recognition of family IV bromodomain‐containing proteins
Lloyd, J. T., & Glass, K. C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26010 · Cited by 88
Cheng, C., Cui, H., Zhang, L., Jia, Z., Song, B., Wang, F., Li, Y., Liu, J., Kong, P., Shi, R., et al. (2016) · GigaScience · doi:10.1186/s13742-015-0107-0 · Cited by 88
SURVIV for survival analysis of mRNA isoform variation
Shen, S., Wang, Y., Wang, C., Wu, Y. N., & Xing, Y. (2016) · Nature Communications · doi:10.1038/ncomms11548 · Cited by 95
Goeman, F., Nicola, F. D., Scalera, S., Sperati, F., Gallo, E., Ciuffreda, L., Pallocca, M., Pizzuti, L., Krasniqi, E., Barchiesi, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.003 · Cited by 97
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
Gong, M., Li, Y., Ye, X., Zhang, L., Wang, Z., Xu, X., Shen, Y., & Zheng, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00568-z · Cited by 86
Otsubo, K., Kishimoto, J., Ando, M., Kenmotsu, H., Minegishi, Y., Horinouchi, H., Kato, T., Ichihara, E., Kondo, M., Atagi, S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00380-2022 · Cited by 98
Lung Stem and Progenitor Cells in Tissue Homeostasis and Disease
Leeman, K. T., Brainson, C. F., & Kim, C. F. (2014) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416022-4.00008-1 · Cited by 99
ROS1 fusions in Chinese patients with non-small-cell lung cancer
Cai, W., Li, X., Su, C., Fan, L., Zheng, L.-M., Fei, K., Zhou, C., Manegold, C., & Schmid‐Bindert, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt071 · Cited by 90
Chen, F., Zhang, Y., Gibbons, D. L., Deneen, B., Kwiatkowski, D. J., Ittmann, M., & Creighton, C. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3378 · Cited by 94
Göke, F., Franzen, A., Hinz, T. K., Marek, L. A., Yoon, P., Sharma, R. K., Bode, M., von Maessenhausen, A., Lankat–Buttgereit, B., Göke, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3357 · Cited by 89
Shahabi, S., Kumaran, V., Castillo, J., Cong, Z., Nandagopal, G., Mullen, D. J., Alvarado, A., Correa, M. R., Saizan, A., Goel, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2034 · Cited by 89
Effects of TP53 mutational status on gene expression patterns across 10 human cancer types
Parikh, N., Hilsenbeck, S. G., Creighton, C. J., Dayaram, T., Shuck, R. L., Shinbrot, E., Liu, X., Gibbs, R. A., Wheeler, D. A., & Donehower, L. A. (2013) · The Journal of Pathology · doi:10.1002/path.4321 · Cited by 91
Re-thinking cell cycle regulators: the cross-talk with metabolism
Fajas, L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00004 · Cited by 101
Feigin, M. E., Xue, B., Hammell, M. C., & Muthuswamy, S. K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320239111 · Cited by 85
Vidyasagar, M. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124502 · Cited by 85
RB constrains lineage fidelity and multiple stages of tumour progression and metastasis
Walter, D. M., Yates, T. J., Ruiz-Torres, M., Kim-Kiselak, C., Gudiel, A. A., Deshpande, C., Wang, W. Z., Cicchini, M., Stokes, K. L., Tobias, J. W., et al. (2019) · Nature · doi:10.1038/s41586-019-1172-9 · Cited by 84
The expression profile and clinic significance of the SIX family in non-small cell lung cancer
Liu, Q., Li, A., Tian, Y., Liu, Y., Li, T., Zhang, C., Wu, J. D., Han, X., & Wu, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0339-1 · Cited by 90
Liu, L., Liu, J., Шао, Д., Deng, Q., Tang, H., Zu, L., Chen, X., Guo, F., Lin, Y., Mao, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13410 · Cited by 90
Fan, Y., Liu, B., Chen, F., Song, Z., Han, B., Meng, Y., Hou, J., Cao, P., Chang, Y., & Tan, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612144 · Cited by 94
Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma
Hedberg, M. L., Berry, C. T., Moshiri, A. S., Xiang, Y., Yeh, C. J., Atillasoy, C., Capell, B. C., & Seykora, J. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073478 · Cited by 108
Mangiante, L., Alcala, N., Sexton‐Oates, A., Genova, A. D., González-Pérez, A., Khandekar, A., Bergstrom, E. N., Kim, J., Liu, X., Blázquez‐Encinas, R., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01321-1 · Cited by 106
Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S., Fontes, C., Shi, Y., Chalasani, P., & Jänne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
MET in human cancer: germline and somatic mutations
Tovar, E. A., & Graveel, C. R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.64 · Cited by 83
Gandara, D. R., Li, T., Lara, P. N., Kelly, K., Riess, J. W., Redman, M. W., & Mack, P. C. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.10.001 · Cited by 83
The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
Öjlert, Å. K., Halvorsen, A. R., Nebdal, D. J. H., Lund‐Iversen, M., Solberg, S. K., Brustugun, O. T., Lingjærde, O. C., & Helland, Å. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12475 · Cited by 93
Gatti, V., Fierro, C., Annicchiarico‐Petruzzelli, M., Melino, G., & Peschiaroli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12473 · Cited by 99
Robertson, H., Dinkova‐Kostova, A. T., & Hayes, J. D. (2020) · Cancers · doi:10.3390/cancers12123609 · Cited by 104
Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J., & Carpizo, D. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.006 · Cited by 83
Yang, Z., Jones, A., Widschwendter, M., & Teschendorff, A. E. (2015) · Genome biology · doi:10.1186/s13059-015-0699-9 · Cited by 92
Kim, D., Li, R., Dudek, S. M., & Ritchie, M. D. (2013) · BioData Mining · doi:10.1186/1756-0381-6-23 · Cited by 83
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.